Cost-Effectiveness of Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Older Patients With High-Risk Myelodysplastic Syndrome: Analysis of BMT CTN 1102.
Wael SaberAasthaa BansalLily LiBart L ScottLindsey R SangaralinghamViengneesee ThaoJoshua A RothWinona WrightLotte M G SteutenJoseph A PidalaAsmita MishraRichard T MaziarzPeter WesterveltJoseph P McGuirkCorey S CutlerRyotaro NakamuraScott D RamseyPublished in: JCO oncology practice (2024)
Among patients age 65 years and older with high-risk MDS, RIC HCT is a high-value strategy. For those age 50-64 years, HCT is a lower-value strategy but has similar cost-effectiveness to other therapies commonly used in oncology.